期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

核苷类似物治疗慢性乙型肝炎耐药现状及进展 被引量：9

The state of the art for the management of antiviral resistance and therapeutic progress of chronic hepatitis B
原文传递
导出
摘要 乙型肝炎病毒（hepatitis B virus,HBV）感染呈世界性流行。口服核苷（酸）类似物（nucleostide analogues,NAs）是治疗慢性乙型肝炎（chronic hepatitis B,CHB）的重要选择;抗病毒治疗过程中出现的耐药问题成为了影响其临床效果的主要因素;因此在使用NAs治疗过程中,
作者 付艳玲 余祖江
机构地区 郑州大学第一附属医院感染科
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2015年第4期370-373,共4页 Chinese Journal of Practical Internal Medicine
基金 国家自然科学基金(81302593)
关键词 慢性乙型肝炎 耐药 准种 核苷(酸)类似物 chronic hepatitis B antiviral resistance quasispecies nucleos（t）ide analogues
分类号 R512.6 [医药卫生—内科学]
  • 相关文献

参考文献29

  • 1Liu Fj Chen Lj Yu D, et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral ei:ficacy[J]. Gut, 2011, 60(9): 1269-1277.
  • 2Chen L, Zhang q Yu DM, et al. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy[J]. J Hepatol, 2009, 50(5): 895-905.
  • 3Rodriguez-Frias F1, Tabernero D, Q uer J, et al. Ultra-Deep Pyrosequencing Detects Conserved Genomic Sites and Quantifies Linkage of Drug-Resistant Amino Acid Changes in the Hepatitis B Virus Genome[J]. PLoS One, 2012, 7(5): e37874, doi: 10.1371/ journal.pone.0037874.
  • 4Chert L, Zhang Q, Yu DM, et al. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy[J]. J Hepatol, 2009,50(5): 895-905.
  • 5Cheng Y, Guindon S, Rodrigo A, et al. Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy[J].J Hepatol, 2013, 58(2): 217-224.
  • 6Lavocat F, Deny P, Pichoud C, et al. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy[J].J Hepatol, 2013, 59(4): 684-695.
  • 7van Bommel F, Trojan J, Deterding K, et al. Evolution of adefovir- resistant HBV polymerase gene variants after switching to tenofovir disoproxil fumarate monotherapy[J]. Antivir her, 2012, 17(6): 1049- 1058.
  • 8Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade[J]. Clin Mol Hepatol, 2013, 19(3): 195-209.
  • 9Koffi J, Egounlety R, Pradat P, et al. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B[J]. Eur J Gastroenterol Hepatol, 2014, 26(2): 146-154.
  • 10Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B [J]. Hepatolog, 2013.

二级参考文献23

  • 1Zoulim F. Are novel combination therapies needed for chronic hepatitis B[J]. ? Antiviral Res, 2012, 96(2): 256-259.
  • 2Segovia MC, Chacra W, Gordon SC. Adefovir dipivoxil in chronic hepatitis B: history and current uses[J]. Expert Opin Pharmacother, 2012, 13(2): 245-254.
  • 3Liu Y, Zhong Y, Zou Z, et al. Features and clinical implications of Hepatitis B virus genotypes and mutation in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B[J].J Clin Virol, 2010, 47(3): 243-247.
  • 4Kim JW, Lee HS, Woo GH, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionine- aspartate- aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy[J]. Clin Infect Dis, 2001, 33(3): 403-405.
  • 5Peters MG, Harm HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine- resistant chronic hepatitis B [J]. Gastroenterology, 2004, 126(1): 91-101.
  • 6Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long- term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years [J]. Gastroenterology, 2006, 131(6): 1743-1751.
  • 7Chen CH, Wang JH, Lu SN, et al. Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience[J]. Liver Int, 2011, 31(2): 206-214.
  • 8Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management [J]. Hepatology, 2007, 46 ( 1): 254-265.
  • 9Ji D, Liu Y, Li L, et al. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation[J]. J Clin Virol, 2012, 54(1): 66-72.
  • 10Andreani T. HBV-cmviers:When is monitoring and surveillance suf- ficient? (point of view) [J]. Clinics and Research in Hepatology and Gastroenterology,2011 : 35 ( 12 ) : 813 - 818.

共引文献23

同被引文献107

  • 1于红缨,邵凌云,符政远,蒋建勇,王菲菲,王金蕾,孟成艳,张文宏.湖南省怀化市少数民族及汉族慢性乙型肝炎患者病毒基因分型及临床分析[J].中华实验和临床感染病杂志（电子版）,2008,2(1):44-49. 被引量：8
  • 2戚世媛,熊正英.女贞子提取物对大鼠肝组织自由基代谢和运动能力的影响[J].西安交通大学学报（医学版）,2012,33(4):507-509. 被引量：10
  • 3卜范峰,鲁艳芹,韩金祥,王丽娜,冯照雷,沈忠林,高刚.乙型肝炎病毒基因型、拉米夫定耐药突变的RFLP检测及临床相关性分析[J].山东大学学报（医学版）,2007,45(11):1139-1143. 被引量：2
  • 4郭红英,张继明.替诺福韦酯治疗慢性乙型肝炎的研究进展[J].世界临床药物,2007,28(12):734-737. 被引量：7
  • 5Marcellin P,Heathcote EJ,Buti M,et al.Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J].N Engl J Med,2008,359(23):2442-2455.
  • 6Lau DT,Bleibel W.Current status of antiviral therapy for hepatitis B[J].Therap Adv Gastroenterol,2008,1(1):61-75.
  • 7Marcellin P,Gane EJ,Tsai N,et al.Seven years of treatment with tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological,biochemical and serological response with no detectable resistance[J].Hepatology,2013,58(Suppl1):649A.
  • 8Marcellin P,Gane E,Buti M,et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet,2013,381(9865):468-475.
  • 9Fung S,Kwan P,Fabri M,et al.Randomized Comparison of Tenofovir Disoproxil Fumarate vs Emtricitabine and Tenofovir Disoproxil Fumarate in Patients with Lamivudine-resistant Chronic Hepatitis B[J].Gastroenterology,2014,146(4):980-988.
  • 10Berg T,Zoulim F,Moeller B,et al.Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients[J].J Hepatol,2014,60(4):715-722.

引证文献9

二级引证文献38

中国实用内科杂志
2015年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部